Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Chiara Cassani

10PUBLICATIONS
158CO-AUTHORS
Predictive and prognostic markersHaematological tumoursRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Reproduction
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

Sort by Publication Date:
|May 06, 2026
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.

|Mar 26, 2026
Revisiting Urological Injury Risks in Minimally Invasive Hysterectomy for Benign Indications: A Rare-Events Network Meta-Analysis with Sensitivity Analyses.

Chiara Cassani, Arsenio Spinillo, Mattia Dominoni

|Dec 15, 2025
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.

Alessio Carbone, Elena Biagioli, Vanda Salutari

|Aug 06, 2025
Quality of radiation shapes survival, invasiveness, and migration in ovarian cancer cell lines with different molecular profiles and varying alpha/beta ratios: an in vitro study on behalf of the Multicenter Italian Trials in Ovarian Cancer (MITO) group.

Amelia Barcellini, Alexandra Charalampopoulou, Gustavo Baldassarre

|Feb 05, 2024
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.

Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli

|Jan 11, 2024
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.

Margherita Turinetto, Andrea Ricotti, Claudia Marchetti

Pageof 2

Frequent Collaborators

4 joint publications

Sandro Pignata

3 joint publications

Ester Orlandi

3 joint publications

Amelia Barcellini

2 joint publications

Giovanni Scambia

2 joint publications

Alexandra Charalampopoulou

2 joint publications

Giorgio Valabrega

2 joint publications

Giorgia Mangili

2 joint publications

Fabio Landoni

2 joint publications

Alice Bergamini

1 joint publications

Michael J Seckl

Frequent Collaborators

4 joint publications

Sandro Pignata

3 joint publications

Ester Orlandi

3 joint publications

Amelia Barcellini

2 joint publications

Giovanni Scambia